Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent S...(oractivity seen to date with bavituximab...)

Date:3/3/2008

or activity seen to date with bavituximab," said Dr. Thorpe, professor of pharmacology at UT Southwestern and a member of Peregrine's Scientific Resource Board. "Bavituximab's ability to achieve unusually clear images of tumors in living animals also suggests that it might have utility for the non-invasive imaging of tumors in cancer patients. Although the study was conducted in rats bearing prostate tumors, we expect that the observations will extend to other solid tumor types as well."

In the study, researchers administered radiolabeled bavituximab to rats with prostate tumors and then conducted molecular imaging studies of the rats over the next several days. The results showed that radiolabeled bavituximab localized to the tumor blood vessels with great specificity. In these subjects, 22 times as much bavituximab localized to the tumor compared to the liver when measured 72 hours post-injection. The study further showed no specific localization of bavituximab to blood or other tissues including the heart, kidney, intestine, muscle, bone and brain. The tumor blood vessel-selective targeting observed in vivo in the study was confirmed by further bio-distribution analyses and by histology studies.

"This important new peer-reviewed study reinforces earlier evidence that bavituximab targets tumor blood vessels with excellent specificity," said Steven W. King, president and CEO of Peregrine. "As we continue to advance the cancer clinical program for bavituximab, these types of studies are expanding the body of scientific evidence demonstrating the highly specific nature of bavituximab's ability to target PS on tumor blood vessels."

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobi
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
3. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
4. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
5. Research by Case Western Reserve University, VA earns cover of prestigious science publication
6. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
7. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
8. Industry Executives Finding Value in Shift of Scientific Publications
9. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
10. Nventa announces publication of HspE7 data
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients